To view this email as a web page, click here.
January 17, 2018
 
ISSUE ALERT
Volume 44, Issue 1
Check out the digital edition!
 
Decreasing burden of nAMD therapy
image description here Patients with neovascular agerelated macular degeneration treated with ranibizumab 100 mg/mL delivered via the port delivery system in a phase II study went a median of 15 months before needing a device refill. A phase III study is under way, says Carl D. Regillo, MD.

Learn more
 
Exfoliation syndrome insights
image description here Elucidation of the mechanisms leading to the development of exfoliation syndrome hold the key to non-IOP-lowering interventions that might prevent or reverse disease, according to Robert Ritch, MD.

Read more
 
A renewed vision
image description here In his latest editorial, OT Chief Medical Editor Peter J. McDonnell, MD, shares the story of how an unforgettable patient could see—and speak out—again.

Continue
 
ADVERTISEMENT
Ad description here
 

This is a post-only, outbound email. Please do not reply to this email as we will be unable to respond to your reply. Please use the links provided if you have questions or concerns regarding this email or your subscription.